Xiaofei Lin1, Zhengyan Wang2, Yumei Wang3, Weijing Feng4. 1. Department of Pediatric Intensive Care Units, Huai'an Maternity and Child Health Hospital of Yangzhou University Huai'an 223002, Jiangsu Province, P.R. China. 2. Department of Pediatrics, Huai'an Hospital Affiliated of Xuzhou Medical College and Huai'an Second People's Hospital 62 Huaihai Road South, Huai'an 223002, P.R. China. 3. Department of Child Health Care, Huai'an Maternity and Child Health Hospital of Yangzhou University Huai'an 223002, P.R. China. 4. Department of Pediatrics, Huai'an First People's Hospital, Nanjing Medical University 6 Beijing Road West, Huai'an, Jiangsu 223300, P.R. China.
Abstract
BACKGROUND: Controversial data on the expression pattern of microRNA-370 (miR-370) in acute myeloid leukemia (AML) were previously reported. OBJECTIVE: To clarify the expression pattern of miR-370 and its clinical implications in pediatric AML patients. METHODS: Real-time quantitative PCR was performed to detect the expression of miR-370 in both bone marrow mononuclear cells and sera obtained from pediatric AML patients and healthy controls. RESULTS: Compared with healthy controls, the expression levels of miR-370 in the bone marrow and sera of pediatric AML patients were both decreased significantly (both P=0.001). Importantly, serum miR-370 level could efficiently screen pediatric AML patients from healthy controls (Area under receiver operating characteristic curve, AUC =0.993). Then, low serum miR-370 level was significantly associated with French-American-British (FAB) classification subtype M7 subtype (P=0.02) and unfavorable karyotype (P=0.01). Moreover, pediatric AML patients with low serum miR-370 level had shorter relapse-free and overall survivals than those with high serum miR-370 level (both P=0.001). Multivariate analysis further identified serum miR-370 level as an independent prognostic factor for both relapse-free and overall survivals. Interestingly, the prognostic relevance of serum miR-370 level was more obvious in the subgroup of patients with intermediate-risk cytogenetics. CONCLUSIONS: MiR-370 expression may be markedly and consistently decreased in pediatric AML patients and in turn contributes to aggressive progression of this malignancy. Serum miR-370 may serve as a potential non-invasive diagnostic/prognostic marker for pediatric AML patients.
BACKGROUND: Controversial data on the expression pattern of microRNA-370 (miR-370) in acute myeloid leukemia (AML) were previously reported. OBJECTIVE: To clarify the expression pattern of miR-370 and its clinical implications in pediatric AMLpatients. METHODS: Real-time quantitative PCR was performed to detect the expression of miR-370 in both bone marrow mononuclear cells and sera obtained from pediatric AMLpatients and healthy controls. RESULTS: Compared with healthy controls, the expression levels of miR-370 in the bone marrow and sera of pediatric AMLpatients were both decreased significantly (both P=0.001). Importantly, serum miR-370 level could efficiently screen pediatric AMLpatients from healthy controls (Area under receiver operating characteristic curve, AUC =0.993). Then, low serum miR-370 level was significantly associated with French-American-British (FAB) classification subtype M7 subtype (P=0.02) and unfavorable karyotype (P=0.01). Moreover, pediatric AMLpatients with low serum miR-370 level had shorter relapse-free and overall survivals than those with high serum miR-370 level (both P=0.001). Multivariate analysis further identified serum miR-370 level as an independent prognostic factor for both relapse-free and overall survivals. Interestingly, the prognostic relevance of serum miR-370 level was more obvious in the subgroup of patients with intermediate-risk cytogenetics. CONCLUSIONS:MiR-370 expression may be markedly and consistently decreased in pediatric AMLpatients and in turn contributes to aggressive progression of this malignancy. Serum miR-370 may serve as a potential non-invasive diagnostic/prognostic marker for pediatric AMLpatients.
Authors: Lucy A Godley; John Cunningham; M Eileen Dolan; R Stephanie Huang; Sandeep Gurbuxani; Megan E McNerney; Richard A Larson; Hoyee Leong; Yves Lussier; Kenan Onel; Olatoyosi Odenike; Wendy Stock; Kevin P White; Michelle M Le Beau Journal: Semin Oncol Date: 2011-04 Impact factor: 4.929
Authors: H Yoshino; T Chiyomaru; H Enokida; K Kawakami; S Tatarano; K Nishiyama; N Nohata; N Seki; M Nakagawa Journal: Br J Cancer Date: 2011-02-08 Impact factor: 7.640
Authors: Angela Galardi; Marta Colletti; Virginia Di Paolo; Patrizia Vitullo; Loretta Antonetti; Ida Russo; Angela Di Giannatale Journal: Int J Mol Sci Date: 2019-09-17 Impact factor: 5.923
Authors: Ajaz A Bhat; Salma N Younes; Syed Shadab Raza; Lubna Zarif; Sabah Nisar; Ikhlak Ahmed; Rashid Mir; Sachin Kumar; Surender K Sharawat; Sheema Hashem; Imadeldin Elfaki; Michal Kulinski; Shilpa Kuttikrishnan; Kirti S Prabhu; Abdul Q Khan; Santosh K Yadav; Wael El-Rifai; Mohammad A Zargar; Hatem Zayed; Mohammad Haris; Shahab Uddin Journal: Mol Cancer Date: 2020-03-12 Impact factor: 27.401